Vaxart Reports Positive Topline Results in Norovirus Vaccine Trial in Lactating Women
    Vaxart Reports Positive Topline Results in Norovirus Vaccine Trial in Lactating Women
    PRISM Biotech

    May 03, 2024  - by Catie Corcoran

    Vaxart Reports Positive Topline Results in Norovirus Vaccine Trial in Lactating Women

    03 May 2024

    New York, May 03, 2024 - PRISM MarketView - Vaxart, Inc. (Nasdaq: VXRT) has reported positive topline results from a Phase 1 clinical trial evaluating its oral pill bivalent norovirus vaccine candidate in lactating women. The company’s long-term goal is to provide protection to infants through passive antibody transfer through their mother’s breast milk. Vaxart’s share price settled up 6.91% in trading on Thursday as the market responded to the news.
    Vaxart, Inc. - Prism MarketView

    Vaxart, Inc. - Prism MarketView

    Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary ora

    Read More

    Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

    Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

    Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody transfer SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed the topline analysis for the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate. The trial was focused on lactating mothers. Antibodies to norovirus rose on average 4.0 fold for

    Read More

    The study demonstrated that antibodies to norovirus rose on average 4.0 fold (G1.1 virus strain) and 6.0 fold (GII.4 virus strain) in the breast milk of lactating mothers who received the Vaxart vaccine candidate in the high dose group.

    “This is an important step forward as we drive toward a vaccine candidate that may make it possible for mothers to protect their children against this highly contagious – and potentially lethal – virus. It can be difficult to immunize the youngest of children mucosally because the immune system is still developing. Passive transfer of antibodies from mothers to infants via breast milk is an innovative approach to potentially improve infection resistance in infants.”

    Dr. James F. Cummings, Vaxart’s Chief Medical Officer

    Norovirus affects approximately 21 million people in the United States each year and has no approved vaccine. Vaxart stated there were no vaccine-related serious adverse events (SAEs) and no dose-limiting pharmacotoxicity as a result of dosing in the study.
    The multi-center, randomized, double-blind, placebo-controlled single dose, dose-ranging study was conducted in South Africa, and was partially funded by the Bill & Melinda Gates Foundation.
    About Vaxart
    Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
    Vaxart, Inc. (Nasdaq: VXRT) is listed on PRISM Emerging Biotech Index
    To see this content properly accept cookies.
    About PRISM MarketView
    Established in 2020, PRISM MarketView is dedicated to monitoring and analyzing small-cap stocks in emerging sectors. We offer up-to-the-minute financial news, provide comprehensive investment tools, and foster a dynamic community of investors. Central to our offerings are proprietary indices that track emerging sectors, including biotechnology, clean energy, next-generation technology, medical devices, and more. Visit us at prismmarketview.com and follow us on Twitter.
    To see this content properly accept cookies.
    Disclaimer:
    PRISM MarketView is not a registered or authorized broker-dealer or investment advisor and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    Prism MarketView | Stock Market News and Investment Opportunities
    To see this content properly accept cookies.
    PRISM MarketView - Social Media (X)
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.